1395281-64-7Relevant articles and documents
N-(3-PYRIDYL) BIARYLAMIDES AS KINASE INHIBITORS
-
Page/Page column 52, (2014/03/25)
The present invention provides a compound of formula (I): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula (I), and pharmaceutical compositions comprising such compounds.
NOVEL AMINOTHIAZOLE CARBOXAMIDES AS KINASE INHIBITORS
-
Page/Page column 64, (2014/03/25)
The present invention provides a compound of formula (I), as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kina
ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS
-
Page/Page column 161, (2014/07/08)
The present invention provides a compound of formula (I) as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula (I), and pharmaceutical compositions comprising such compounds.
TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS
-
, (2012/09/11)
The present invention provides a compound of formula (I): as further described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.
NOVEL KINASE INHIBITORS
-
, (2012/09/11)
The present invention provides compounds of Formula I: and related compounds as further described herein, and pharmaceutical compositions comprising these compounds. The invention further provides methods to use these compounds and compositions for treating disorders associated with undesired levels of Pim kinase activity, including cancers and autoimmune disorders.
